{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Sun Pharmaceutical Industries Ltd
P/E at 36.57 vs Industry's 34.48: What the Data Shows for Sun Pharmaceutical Industries Ltd
A price-to-earnings ratio of 36.57 against an industry average of 34.48 represents a modest premium for Sun Pharmaceutical Industries Ltd. Previously rated Buy by MarketsMOJO, the company’s rating was reassessed on 5 May 2026. While the one-year return of 3.46% outpaces the Sensex’s decline of 3.50%, the stock’s short-term momentum remains mixed, revealing a nuanced performance across different timeframes.
Broad-Based Technical Strength Lifts Sun Pharmaceutical Industries Ltd to 52-Week High of Rs 1843.95
With a close approach to its 52-week high at Rs 1843.95 on 6 Jun 2026, Sun Pharmaceutical Industries Ltd has demonstrated notable price momentum, supported by a broad alignment of technical indicators across weekly and monthly timeframes.
Sun Pharmaceutical Industries Ltd Upgraded to Strong Buy on Robust Fundamentals and Technicals
Sun Pharmaceutical Industries Ltd has been upgraded from a Buy to a Strong Buy rating, reflecting significant improvements across quality, valuation, financial trends, and technical indicators. This upgrade, announced on 5 May 2026, underscores the company’s solid fundamentals, bullish technical momentum, and favourable market positioning within the Pharmaceuticals & Biotechnology sector.
Sun Pharmaceutical Industries Ltd Technical Momentum Shifts Signal Bullish Outlook
Sun Pharmaceutical Industries Ltd has witnessed a notable shift in its technical momentum, with key indicators signalling an increasingly bullish trend. Despite a minor day decline of 0.18%, the stock’s underlying technical parameters and long-term returns suggest a robust outlook for investors in the pharmaceuticals and biotechnology sector.
P/E at 36.04 vs Industry's 33.77: What the Data Shows for Sun Pharmaceutical Industries Ltd
A price-to-earnings ratio of 36.04 against an industry average of 33.77 marks a notable premium for Sun Pharmaceutical Industries Ltd. Previously rated Hold by MarketsMOJO, the stock’s rating was reassessed on 27 Apr 2026. While the one-year return marginally trails the Sensex, the three-month performance reveals a sharp divergence, painting a complex picture of momentum and valuation.
P/E at 35.73 vs Industry's 33.40: What the Data Shows for Sun Pharmaceutical Industries Ltd
A price-to-earnings ratio of 35.73 against an industry average of 33.40 represents a modest premium for Sun Pharmaceutical Industries Ltd. Previously rated Hold by MarketsMOJO, the company’s rating was reassessed on 27 Apr 2026. While the one-year return marginally outperforms the Sensex, the stock’s recent momentum and technical positioning reveal a more nuanced picture.
Sun Pharmaceutical Gains 11.62%: 5 Key Factors Driving the Week’s Rally
Sun Pharmaceutical Industries Ltd delivered a strong weekly performance, gaining 11.62% from Rs.1,619.95 to Rs.1,808.20 between 27 April and 30 April 2026, significantly outperforming the Sensex’s modest 0.47% rise. The stock’s rally was supported by robust trading volumes, institutional interest, and a notable upgrade in its Mojo Grade, reflecting renewed investor confidence amid mixed technical signals and active options market positioning.
11,697 Call Contracts Traded on Sun Pharmaceutical Industries Ltd as Stock Climbs 1.52%
On 30 Apr 2026, 11,697 call contracts on Sun Pharmaceutical Industries Ltd exchanged hands at the Rs 1,800 strike price, closely aligned with the stock’s closing price of Rs 1,800.30. This synchrony between the options and cash markets highlights a focused directional stance as the stock continues its four-day rally, gaining 1.52% on the day.
P/E at 35.15 vs Industry's 33.42: What the Data Shows for Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd continues to assert its prominence within the Nifty 50 index, bolstered by a recent upgrade in its Mojo Grade to 'Buy' and sustained institutional interest. Despite a minor dip in share price, the company’s robust fundamentals and sector-leading performance underscore its pivotal role in India’s pharmaceuticals and biotechnology landscape.
Sun Pharmaceutical Industries Ltd Sees Robust Trading Activity Amid Institutional Interest
Sun Pharmaceutical Industries Ltd, a leading player in the Pharmaceuticals & Biotechnology sector, has witnessed significant trading activity with a strong value turnover and rising institutional participation. The stock continues its upward trajectory, supported by favourable technical indicators and a recent upgrade in its investment rating, signalling renewed investor confidence.
P/E at 34.6 vs Industry's 33.3: What the Data Shows for Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd, a stalwart in the Pharmaceuticals & Biotechnology sector and a key constituent of the Nifty 50 index, has demonstrated renewed momentum with a notable upgrade in its investment grade and sustained institutional interest. This development underscores the company's growing significance within the benchmark index and highlights evolving market perceptions amid sectoral and broader market trends.
Sun Pharmaceutical Sees Robust Value Trading Amid Institutional Interest
Sun Pharmaceutical Industries Ltd, a stalwart in the Pharmaceuticals & Biotechnology sector, has emerged as one of the most actively traded stocks by value on 28 April 2026, reflecting heightened investor interest and strong institutional participation. The stock’s performance, liquidity, and technical indicators suggest a positive outlook, supported by an upgrade in its Mojo Grade from Hold to Buy.
Sun Pharmaceutical Industries Ltd Upgraded to Buy by MarketsMOJO on Strong Fundamentals and Technicals
Sun Pharmaceutical Industries Ltd has seen its investment rating upgraded from Hold to Buy, driven by a combination of improved technical indicators, robust financial performance, and strong quality metrics. The upgrade reflects a positive shift in the company’s outlook amid a mildly bullish technical trend and sustained fundamental strength, positioning it favourably within the Pharmaceuticals & Biotechnology sector.
Sun Pharmaceutical Industries Ltd Shows Renewed Momentum Amid Mixed Technical Signals
Sun Pharmaceutical Industries Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. This change is underscored by a 7.03% surge in the stock price to ₹1,733.80 on 28 Apr 2026, signalling renewed investor interest despite mixed signals from key technical indicators such as MACD, RSI, and moving averages.
Sun Pharmaceutical Industries Ltd Sees Robust Trading Activity Amid Sector Gains
Sun Pharmaceutical Industries Ltd (SUNPHARMA) emerged as one of the most actively traded stocks by value on 27 Apr 2026, registering a significant 7.10% gain in a day that saw the Pharmaceuticals & Biotechnology sector advance by 2.32%. The stock’s strong performance was underpinned by heightened investor participation, robust volume, and notable institutional interest, reflecting renewed confidence in the large-cap pharmaceutical giant despite a recent downgrade in its mojo grade.
Rs 1,660 Puts — 3.9% Below Current Price — Draw 3,061 Contracts on Sun Pharmaceutical Industries Ltd
Rs 1,660 put options on Sun Pharmaceutical Industries Ltd attracted 3,061 contracts on 27 Apr 2026, representing notable activity at a strike 3.9% below the current stock price of Rs 1,728. This surge in put trading invites a closer look at whether the market is signalling caution, protection, or a more nuanced positioning.
At-the-Money Calls on Sun Pharmaceutical Industries Ltd Draw 6,161 Contracts — A Signal of Immediate Directional Conviction
6,161 call contracts at the Rs 1,750 strike price changed hands on Sun Pharmaceutical Industries Ltd on 27 Apr 2026, with the stock closing at Rs 1,728. The near parity between the strike and the underlying price highlights a strong directional bet, supported by a 7.10% rally in the cash market.
Sun Pharmaceutical Industries Ltd Surges 4.1% to Day's High of Rs 1709.25 — Outperforms Sector by 4.79 Percentage Points
The Sensex advanced 0.66% on 27 Apr 2026, yet Sun Pharmaceutical Industries Ltd outpaced the broader market with a 4.1% gain, touching an intraday high of Rs 1709.25. This 4.79-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers highlights a distinctly stock-specific rally rather than a general market lift.
P/E at 31.98 vs Industry's 32.51: What the Data Shows for Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd, a stalwart in the Pharmaceuticals & Biotechnology sector and a prominent Nifty 50 constituent, has experienced a notable shift in market dynamics and institutional interest. Despite a recent downgrade in its Mojo Grade from Buy to Hold, the stock’s large-cap status and benchmark index membership continue to underpin its significance for investors navigating the evolving Indian equity landscape.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
